Cargando…
M098 A CASE OF HEREDITARY A-TRYPTASEMIA EXACERBATION FOLLOWING SECOND DOSE OF MRNA COVID-19 VACCINE ON OMALIZUMAB
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Published by Elsevier Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566848/ http://dx.doi.org/10.1016/j.anai.2021.08.252 |
| _version_ | 1784594104948097024 |
|---|---|
| author | Li, J. Saff, R. |
| author_facet | Li, J. Saff, R. |
| author_sort | Li, J. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8566848 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Published by Elsevier Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-85668482021-11-04 M098 A CASE OF HEREDITARY A-TRYPTASEMIA EXACERBATION FOLLOWING SECOND DOSE OF MRNA COVID-19 VACCINE ON OMALIZUMAB Li, J. Saff, R. Ann Allergy Asthma Immunol Article Published by Elsevier Inc. 2021-11 2021-11-04 /pmc/articles/PMC8566848/ http://dx.doi.org/10.1016/j.anai.2021.08.252 Text en Copyright © 2021 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Article Li, J. Saff, R. M098 A CASE OF HEREDITARY A-TRYPTASEMIA EXACERBATION FOLLOWING SECOND DOSE OF MRNA COVID-19 VACCINE ON OMALIZUMAB |
| title | M098 A CASE OF HEREDITARY A-TRYPTASEMIA EXACERBATION FOLLOWING SECOND DOSE OF MRNA COVID-19 VACCINE ON OMALIZUMAB |
| title_full | M098 A CASE OF HEREDITARY A-TRYPTASEMIA EXACERBATION FOLLOWING SECOND DOSE OF MRNA COVID-19 VACCINE ON OMALIZUMAB |
| title_fullStr | M098 A CASE OF HEREDITARY A-TRYPTASEMIA EXACERBATION FOLLOWING SECOND DOSE OF MRNA COVID-19 VACCINE ON OMALIZUMAB |
| title_full_unstemmed | M098 A CASE OF HEREDITARY A-TRYPTASEMIA EXACERBATION FOLLOWING SECOND DOSE OF MRNA COVID-19 VACCINE ON OMALIZUMAB |
| title_short | M098 A CASE OF HEREDITARY A-TRYPTASEMIA EXACERBATION FOLLOWING SECOND DOSE OF MRNA COVID-19 VACCINE ON OMALIZUMAB |
| title_sort | m098 a case of hereditary a-tryptasemia exacerbation following second dose of mrna covid-19 vaccine on omalizumab |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566848/ http://dx.doi.org/10.1016/j.anai.2021.08.252 |
| work_keys_str_mv | AT lij m098acaseofhereditaryatryptasemiaexacerbationfollowingseconddoseofmrnacovid19vaccineonomalizumab AT saffr m098acaseofhereditaryatryptasemiaexacerbationfollowingseconddoseofmrnacovid19vaccineonomalizumab |